Candel Therapeutics/$CADL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Candel Therapeutics
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Ticker
$CADL
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
38
Website
CADL Metrics
BasicAdvanced
$350M
-
-$1.08
-0.91
-
Price and volume
Market cap
$350M
Beta
-0.91
52-week high
$9.13
52-week low
$4.25
Average daily volume
1M
Financial strength
Current ratio
4.641
Quick ratio
4.592
Long term debt to equity
1.555
Total debt to equity
14.614
Interest coverage (TTM)
-18.78%
Profitability
EBITDA (TTM)
-31.874
Management effectiveness
Return on assets (TTM)
-32.31%
Return on equity (TTM)
-98.14%
Valuation
Price to book
4.33
Price to tangible book (TTM)
4.33
Price to free cash flow (TTM)
-8.932
Free cash flow yield (TTM)
-11.20%
Free cash flow per share (TTM)
-0.736
Growth
Earnings per share change (TTM)
-16.32%
3-year earnings per share growth (CAGR)
-8.47%
Bulls say / Bears say
Positive pivotal topline phase 3 data for CAN-2409 in intermediate-to-high-risk localized prostate cancer, demonstrating potential to redefine the standard of care
FDA granted Regenerative Medicine Advanced Therapy designation to CAN-2409 for newly diagnosed intermediate-to-high-risk localized prostate cancer, providing expedited development and review pathways
Canaccord Genuity initiated coverage with a buy rating and $20 price objective, complemented by Bank of America’s buy rating and $15 target, signaling strong analyst confidence
Net loss of $55.2 million for full year 2024, up from $37.9 million in 2023, reflecting accelerating cash burn and mounting profitability pressure
Closed a $92 million public offering at $6.00 per share in December 2024, diluting existing shareholders and highlighting ongoing capital needs
Biologics License Application (BLA) submission for CAN-2409 not expected until Q4 2026, prolonging the timeline to commercialization and revenue generation
Data summarised monthly by Lightyear AI. Last updated on 17 Jul 2025.
CADL News
AllArticlesVideos
Candel Therapeutics receives EMA Orphan Designation for immunotherapy candidate CAN-2409
Proactive Investors·1 week ago
Candel Therapeutics expands Russell Index presence following 2025 reconstitution
Proactive Investors·3 weeks ago
Candel Therapeutics announces $15M direct offering to support CAN-2409 launch preparations
Proactive Investors·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Candel Therapeutics stock?
Candel Therapeutics (CADL) has a market cap of $350M as of July 31, 2025.
What is the P/E ratio for Candel Therapeutics stock?
The price to earnings (P/E) ratio for Candel Therapeutics (CADL) stock is 0 as of July 31, 2025.
Does Candel Therapeutics stock pay dividends?
No, Candel Therapeutics (CADL) stock does not pay dividends to its shareholders as of July 31, 2025.
When is the next Candel Therapeutics dividend payment date?
Candel Therapeutics (CADL) stock does not pay dividends to its shareholders.
What is the beta indicator for Candel Therapeutics?
Candel Therapeutics (CADL) has a beta rating of -0.91. This means that it has an inverse relation to market volatility.